drugset / Trial / NCT02805049

Pharmacokinetic Study on Echinocandins for Patients With Septic Shock Following Secondary Peritonitis (EPI Study)

NCT02805049

Phase 4 Completed 24 enrolled Nîmes University Hospital
NaSingle-groupOpen-labelTreatment

Summary

The main objective of this study is to describe the pharmacokinetics of the prescribed echinocandins for septic shock with secondary peritonitis for which intra-abdominal fungal infection is suspected or proven.

Timeline

Start
2017-01-28
Primary completion
2018-06-18
Completion
2018-06-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Caspofungin Other / unclassified
Subject Micafungin Peptide 100 mg